Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sunnybrook Health Sciences Centre
Washington University School of Medicine
Institut Jean-Godinot
Fondazione Italiana Linfomi - ETS
M.D. Anderson Cancer Center
University of Rochester
Clinica Universidad de Navarra, Universidad de Navarra
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ascentage Pharma Group Inc.
Canadian Cancer Trials Group
CSPC Megalith Biopharmaceutical Co.,Ltd.
Indiana University
University Health Network, Toronto
Zhongnan Hospital
National Cancer Institute, Egypt
Tongji Hospital
First Affiliated Hospital of Ningbo University
Assistance Publique - Hôpitaux de Paris
University of Pennsylvania
Yonsei University
Medical College of Wisconsin
The First Affiliated Hospital with Nanjing Medical University
Medical College of Wisconsin
Affiliated Hospital of Jiangsu University
AbbVie
University Hospital, Basel, Switzerland
Sun Yat-sen University
Regeneron Pharmaceuticals
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Institute of Hematology & Blood Diseases Hospital, China
Shanghai University of Traditional Chinese Medicine
Telix Pharmaceuticals (Innovations) Pty Limited
Advesya SAS
Biotroy Therapeutics
Princess Maxima Center for Pediatric Oncology
Affiliated Hospital to Academy of Military Medical Sciences
Hangzhou Polymed Biopharmaceuticals, Inc.
Nationwide Children's Hospital
The First Affiliated Hospital with Nanjing Medical University
Shanghai Pulmonary Hospital, Shanghai, China
Guangzhou University of Traditional Chinese Medicine
Chinese PLA General Hospital
Tongji Hospital
National Taiwan University Hospital
The Hospital for Sick Children
Gruppo Italiano Malattie EMatologiche dell'Adulto
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.